NCT07046221

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery: A Prospective, Open-label, Multicenter Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group

Conditions

• Esophagus Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	200mg，d1，q3w，1years
DRUG	Albumin-Bound Paclitaxel	125mg/m2，d1，d8，q3w，2cycles
DRUG	cis-platinum	75mg/m2，d1，q3w，2cycles
PROCEDURE	Surgery	Radical resection of esophageal cancer
RADIATION	Radiation	50.5Gy/28f
DRUG	Nedaplatin	80-100mg/m2，d1，q3w，2cycles
DRUG	Carboplatin	AUC=5，d1，q3w，2cycles

Timeline

• Start date: 2025-08-01
• Primary completion: 2027-08-01
• Completion: 2030-08-01
• First posted: 2025-07-01
• Last updated: 2025-07-20